Current Science

Open Access Open Access  Restricted Access Subscription Access

Biobusiness in Brief:What Ails Clinical Trials?


Affiliations
1 Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City, Phase I, Bengaluru 560 100, India
 

Many academic researchers, while working on fundamental problems, hope that in due course their science will benefit humanity. Undoubtedly, they would be delighted if their science was to be the basis for drugs that reached patients. For that to happen, the candidate molecules must pass through clinical trials. Unfortunately, world over, trials have been beset with problems and have been heavily criticized on many fronts. Here we describe some of the points of contention, focusing on issues that have come to light in the West.

Keywords

Biotech Industry, Clinical Trials, Ethics, Pharma Industry.
User
Notifications
Font Size

  • Ehrhardt, S., Appel, L. J. and Meinert, C. L., Trends in National Institutes of Health funding for clinical trials registered in ClinicalTrials. gov. JAMA, 2015, 314, 2566–2567.

  • Smith, R., Bad medicine. A book review of ‘Bad Pharma. How drug companies mislead doctors and harm patients’ by Ben Goldacre, Fourth Estate. eLife, 2012, 1, e00351.

  • Lexchin, J., Economics and industry do not mean ethical conduct in clinical trials. J. Pharm. Policy Pract., 2013, 6, 11–14.

  • Lewis, T. R., Reichman, J. H. and So, A. D., The case for public funding and public oversight of clinical trials. Econ. Voice, 2007, 4, 1–4.

  • Sekeres, M. A., The disgrace of cancer clinical trials. The Hill blog, 21 December 2016.

  • Sertkaya, A., Birkenbach, A., Berlind, A. and Eyraud, J., Examination of clinical trial costs and barriers for drug development. Report of the US Department of Health and Human Services, Office of the Assistant Secretary of Planning and Evaluation, Washington, DC, 2014.

  • Ouyang, H., Hashtag prescription. The hidden cost of crowd sourcing a cure. Harper’s Magazine, 25 June 2017.

  • Servick, K., ‘Right to Try’ laws bypass FDA for last ditch treatments. Science, 2014, 344, 1329.

  • Caplan, A., Moch, K. I., Watson, T., Roxland, B. and Scheer, D., Right-to-try laws for the terminally ill are bad policy. Forbes, 23 September 2016; https://www.forbes.com/sites/arthurcaplan/2016/09/23/right-to-try-laws-for-the-terminally-ill-are-bad-policy/#608e75a32277

  • Antes, G., Registering clinical trials is necessary for ethical, scientific and economic reasons. Bull. WHO, 2004, 82, 321.

  • De Angelis, C. et al., Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann. Intern. Med., 2004, 141, 477–478.

  • Kaplan, R. M. and Irvin, V. L., Likelihood of null effects of large NHLBI clinical trials has increased over time. PLOS ONE, 2015, 10, e0132382.

  • Moorthy, V. S., Karam, G., Vannice, K. S. and Kieny, M. P., Rationale for WHO’s new position calling for prompt reporting and public disclosure of interventional clinical trial results. PLoS Med., 2015, 12, e1001819.

  • Chen, R. et al., Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ, 2016, 352, i637.

  • Nather, D. and Piller, C., Biden threatens funding cuts for researchers who fail to report clinical trial results. STAT, 29 June 2016; https://www.statnews.com/2016/06/29/biden-clinical-trials-cancer/

  • Anon., Towards greater transparency in clinical trial reporting. Lancet Neurol., 2016, 15, 1295.

  • Anon., Safety first. Nature, 2016, 530, 381.

  • Masterson, A., Bad pharma and the canary in the coalmine for problems in modern medicine. Cosmos, 8 August 2016.

  • Powell-Smith, A. and Goldacre, B., The Trials Tracker: automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions. F1000Research, 2016, 5, 2629–2644.

  • Light, D. W., Lexchin, J. and Darrow, J. J., Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J. Law Med. Ethics, 2013, 41, 590–600.

  • Cook, M., Sanitizing the language of clinical trials. BioEdge, 5 March 2016.

  • Buck, C., Too many whites in drug trials, and minorities are losing out. Am. Renaissance, 27 April 2017.

  • Schumaker, E., Most clinical trials have a glaring flaw before they even begin. The Huffington Post, 23 February 2017.

  • Wilson, R. F., The death of Jesse Gelsinger: new evidence of the influence of money and prestige in human research. Am. J. Law Med., 2010, 36, 295–325.

  • Moore, T. J. and Furberg, C. D., Development times, clinical testing, postmarket followup, and safety risks for the new drugs approved by the US Food and Drug Administration. The class of 2008. JAMA Intern. Med., 2014, 174, 90–95.

  • Berendt, L. et al., From protocol to published report: a study of consistency in the reporting of academic drug trials. Trials, 2016, 17, 100–107.

  • Matheson, A., Marketing trials, marketing tricks – how to spot them and how to stop them. Trials, 2017, 18, 105–110.

  • Heneghan, C., Goldacre, B. and Mahtani, K. R., Why clinical trial outcomes fail to translate into benefits for patients. Trials, 2017, 18, 122–128.


Abstract Views: 410

PDF Views: 114




  • Biobusiness in Brief:What Ails Clinical Trials?

Abstract Views: 410  |  PDF Views: 114

Authors

Gayatri Saberwal
Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City, Phase I, Bengaluru 560 100, India

Abstract


Many academic researchers, while working on fundamental problems, hope that in due course their science will benefit humanity. Undoubtedly, they would be delighted if their science was to be the basis for drugs that reached patients. For that to happen, the candidate molecules must pass through clinical trials. Unfortunately, world over, trials have been beset with problems and have been heavily criticized on many fronts. Here we describe some of the points of contention, focusing on issues that have come to light in the West.

Keywords


Biotech Industry, Clinical Trials, Ethics, Pharma Industry.

References





DOI: https://doi.org/10.18520/cs%2Fv115%2Fi9%2F1648-1652